Bad forecasts. The reps made bonuses first year and now the drug is struggling in the second. My feeling is that they over estimated the disease state population and it looks like they are doing it on an even great scale with Natpara. They hired 35 reps for Gattex and 50 will be hired for Natpara. I think that is a serious misstep for this company. They will cash poor soon and as it is, they are ripe for acquisition which may be a good thing. Who knows? I just think the prospect of Endo being even worse then GI is a real possibility.